Belfast Telegraph

Tuesday 27 January 2015

Drugs giant could sell Lucozade

GlaxoSmithKline could sell Lucozade and Ribena after the UK's biggest pharmaceuticals firm set out plans for a "strategic review" of the drinks brands.

The drugmaker's chief executive, Sir Andrew Witty, said he was focused on the "two places where there are cast-iron synergies between pharma and the consumer business, which are over-the-counter medicines, such as Panadol, and emerging markets.

Lucozade and Ribena are iconic brands, but don't naturally fit into those two places.

Witty said its review, which will be complete by the middle of this year, involved "truly no decisions taken or options ruled out – we could increase investments in certain parts of the world, find a partner, or divest the products."

The announcement came as GSK suffered from European governments cutting back on healthcare and drugs spending, with annual turnover falling 1% to £26.4bn in 2012, and pre-tax profits slipping 4% to £7.6bn. Sales in emerging markets account for just over a quarter of business.

COMMENT RULES: Comments that are judged to be defamatory, abusive or in bad taste are not acceptable and contributors who consistently fall below certain criteria will be permanently blacklisted. The moderator will not enter into debate with individual contributors and the moderator’s decision is final. It is Belfast Telegraph policy to close comments on court cases, tribunals and active legal investigations. We may also close comments on articles which are being targeted for abuse. Problems with commenting?



Company Profiles


Help & Advice


People on the move